Innate Pharma and the Institute for Follicular Lymphoma (IFLI) have partnered to explore the potential of IPH6501, Innate’s anti-CD20 ANKET® therapy, in treating follicular lymphoma (FL). This partnership involves IFLI investing initially $3 million in Innate Pharma, with the potential for an additional $4.9 million based on milestone achievements. This investment will support the inclusion of FL patients in Innate’s ongoing Phase 1/2 trial of IPH6501 in patients with relapsed and/or refractory Non-Hodgkin Lymphoma.
This collaboration addresses the critical need for new treatment options for follicular lymphoma, a slow-growing but incurable form of Non-Hodgkin lymphoma. The partnership combines Innate Pharma’s expertise in immunotherapy development with IFLI’s dedication to accelerating follicular lymphoma research, creating a synergistic effort to advance potential treatments and improve patient outcomes. For Innate Pharma, this collaboration not only provides crucial funding but also validates the potential of IPH6501 as a promising therapeutic candidate.
The agreement outlines a staged investment strategy. The initial $3 million investment by IFLI will be used to support the ongoing Phase 1/2 trial and the specific inclusion of follicular lymphoma patients. This investment translates to IFLI acquiring 2.26% of Innate Pharma’s share capital. The potential follow-on investment of up to $4.9 million is contingent upon the achievement of specific milestones, likely related to clinical trial progress and efficacy data. The price for the potential follow-on investment will be determined at the time of investment.
This partnership signifies a potentially significant advance in follicular lymphoma treatment. The combined resources and expertise of Innate Pharma and IFLI offer a promising pathway for developing much-needed therapies. The success of the Phase 1/2 trial and the achievement of pre-defined milestones could lead to further development of IPH6501, offering renewed hope for patients with follicular lymphoma. This collaboration model also illustrates how philanthropic investment can significantly catalyze therapeutic development within a specific disease area, potentially paving the way for similar partnerships in the future. This ultimately creates a positive outlook for the advancement of follicular lymphoma research and the development of innovative treatment options. The outcome of this trial and subsequent research will be vital in shaping the future treatment landscape for this patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
